INS and metabolic dysfunction-associated steatotic liver disease: Table 1 shows that sCD163 had positive trends with diabetes, dyslipidemia, NAFLD, MetS, BMI, liver injury markers (AST and ALT), TG, glucose biomarkers (HbA1c, insulin, and CML), RBC aggregation, and SF (all p for trend < 0.05). On the other hand, HDL-C had a negative trend with sCD163 concentrations (p for trend = 0.004).